A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 23, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Mar 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IMTX SEC filings page.
This page shows Immatics N.V. (IMTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Immatics N.V. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Immatics N.V. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Immatics N.V. reported a net loss of $230.6M while operations used $207.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Immatics N.V. reported an operating loss of $213.6M against $1.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Immatics N.V.'s EBITDA was -$199.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.
Immatics N.V. reported a net loss of $230.6M in fiscal year 2025. This represents a decrease of 1563.6% from the prior year.
Immatics N.V. earned -$1.89 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 1404.0% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Immatics N.V. recorded an outflow of $215.0M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
Immatics N.V. held $406.0M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.
Not reported for fiscal year 2025.
Margins & Returns
Immatics N.V.'s ROE was -40.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 43.2 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Immatics N.V. invested $215.7M in research and development in fiscal year 2025. This represents an increase of 40.8% from the prior year.
Immatics N.V. invested $7.7M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 54.3% from the prior year.
Not reported for fiscal year 2025.
IMTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $215.7M+40.8% | $153.3M+16.8% | $131.3M+14.9% | $114.2M+15.3% | $99.1M+20.8% | $82.0M+82.3% | $45.0M+15.7% | $38.9M |
| Operating Income | -$213.6Mn/m | -$40.0Mn/m | -$112.5M-451.2% | $32.0Mn/m | -$97.7Mn/m | -$85.3Mn/m | -$37.1Mn/m | -$39.4M |
| EBITDA | -$199.1Mn/m | -$27.3Mn/m | -$104.5M-364.6% | $39.5Mn/m | -$91.7Mn/m | -$79.9Mn/m | -$32.7Mn/m | -$36.9M |
| Interest Expense | $1.1M+21.1% | $917K-0.2% | $919K-17.2% | $1.1M+73.3% | $641K+81.2% | $353K+19.2% | $296K+60.7% | $184K |
| Income Tax | -$2.3M-136.8% | $6.3Mn/m | -$2.6M-116.9% | $15.3Mn/m | $0n/m | $0n/m | $0n/m | $0 |
| Net Income | -$230.6M-1563.6% | $15.8Mn/m | -$104.7M-453.3% | $29.6Mn/m | -$105.6Mn/m | -$258.4Mn/m | -$35.4Mn/m | -$36.0M |
| EPS (Basic) | -$1.89-1404.0% | $0.14n/m | -$1.31-397.6% | $0.44n/m | -$1.68n/m | -$5.38 | N/A | N/A |
| EPS (Diluted) | -$1.89-1404.0% | $0.14n/m | -$1.31-405.0% | $0.43n/m | -$1.68n/m | -$5.38 | N/A | N/A |
| Diluted Shares (Avg) | 122M+14.6% | 107M+32.6% | 81M+17.0% | 69M+9.4% | 63M+31.1% | 48M | N/A | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, SG&A Expenses.
IMTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $660.0M-8.4% | $720.6M+27.7% | $564.1M+29.3% | $436.3M+120.7% | $197.7M-36.5% | $311.4M+106.6% | $150.8M | N/A |
| Current Assets | $591.5M-9.2% | $651.7M+31.1% | $497.1M+23.2% | $403.5M+134.2% | $172.3M-41.1% | $292.3M+110.0% | $139.2M | N/A |
| Cash & Equivalents | $406.0M+65.7% | $245.1M+1.4% | $241.7M+52.1% | $158.9M+5.6% | $150.5M-40.7% | $253.8M+118.7% | $116.0M+157.3% | $45.1M |
| Goodwill | $1.9M+10.1% | $1.7M+0.1% | $1.7M-3.5% | $1.7M+17.3% | $1.5M+33.1% | $1.1M-1.2% | $1.1M | N/A |
| Total Liabilities | $91.8M-26.9% | $125.6M-61.2% | $323.4M+47.8% | $218.7M+28.3% | $170.4M-16.7% | $204.6M+3.4% | $197.7M | N/A |
| Current Liabilities | $50.5M-28.3% | $70.4M-59.4% | $173.2M+52.1% | $113.9M+5.8% | $107.7M+13.6% | $94.8M+21.8% | $77.8M | N/A |
| Non-Current Liabilities | $41.3M-25.1% | $55.2M-63.3% | $150.2M+43.3% | $104.9M+67.1% | $62.7M-42.9% | $109.8M-7.6% | $118.8M | N/A |
| Total Equity | $568.1M-4.5% | $595.0M+147.2% | $240.7M+10.7% | $217.5M+698.8% | $27.2M-74.5% | $106.9Mn/m | -$47.0Mn/m | -$10.5M |
| Retained Earnings | -$922.4Mn/m | -$610.2Mn/m | -$669.0Mn/m | -$545.7Mn/m | -$608.7Mn/m | -$543.6Mn/m | -$261.8M | N/A |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Long-Term Debt.
IMTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$207.3Mn/m | -$163.6M-911.2% | $20.2M-81.2% | $107.1Mn/m | -$95.9Mn/m | -$98.7M-223.9% | $79.7M+236.2% | $23.7M |
| Depreciation & Amortization | $14.6M+15.0% | $12.7M+58.1% | $8.0M+7.4% | $7.5M+25.2% | $6.0M+10.0% | $5.4M+24.9% | $4.3M+73.8% | $2.5M |
| Capital Expenditures | $7.7M-54.3% | $16.8M-50.6% | $34.1M+455.0% | $6.1M+6.2% | $5.8M-36.3% | $9.1M+277.2% | $2.4M+389.5% | $491K |
| Free Cash Flow | -$215.0Mn/m | -$180.4Mn/m | -$13.9M-113.8% | $101.0Mn/m | -$101.7Mn/m | -$107.8M-239.5% | $77.3M+233.0% | $23.2M |
| Investing Cash Flow | $240.3Mn/m | -$157.7Mn/m | -$34.7Mn/m | -$224.4M-2746.5% | $8.5Mn/m | -$19.5Mn/m | -$5.7Mn/m | -$15.5M |
| Financing Cash Flow | $114.3M-65.5% | $330.9M+253.9% | $93.5M-29.4% | $132.3Mn/m | -$3.0M-101.2% | $254.2Mn/m | -$2.1M-107.7% | $27.1M |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
IMTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -40.6%-43.2pp | 2.6%+46.1pp | -43.5%-57.1pp | 13.6%+401.5pp | -387.9%-146.1pp | -241.8% | N/A | N/A |
| Return on Assets | -34.9%-37.1pp | 2.2%+20.8pp | -18.6%-25.4pp | 6.8%+60.2pp | -53.4%+29.5pp | -83.0%-59.5pp | -23.5% | N/A |
| Current Ratio | 11.72+2.5x | 9.26+6.4x | 2.87-0.7x | 3.54+1.9x | 1.60-1.5x | 3.08+1.3x | 1.79 | N/A |
| Liabilities-to-Equity | 0.160.0x | 0.21-1.1x | 1.34+0.3x | 1.01-5.3x | 6.26+4.3x | 1.91 | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Immatics N.V. IMTX | FY2025 | N/A | -$230.6M | N/A | $1.1B | — |
| Tango Therapeutics, Inc. TNGX | FY2025 | $62.4M | -$101.6M | N/A | $3.9B | 66/100 |
| ArriVent BioPharma, Inc. AVBP | FY2025 | N/A | -$166.3M | N/A | $1.0B | — |
| Gyre Therapeutics, Inc. GYRE | FY2025 | $116.6M | $9.9M | 8.5% | $620.3M | 38/100 |
Where Immatics N.V. Ranks
Frequently Asked Questions
Is Immatics N.V. profitable?
No, Immatics N.V. (IMTX) reported a net loss of $230.6M in fiscal year 2025.
What is Immatics N.V.'s EBITDA?
Immatics N.V. (IMTX) had EBITDA of -$199.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Immatics N.V.'s return on equity (ROE)?
Immatics N.V. (IMTX) has a return on equity of -40.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Immatics N.V.'s free cash flow?
Immatics N.V. (IMTX) recorded an outflow of $215.0M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Immatics N.V.'s operating cash flow?
Immatics N.V. (IMTX) recorded an outflow of $207.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Immatics N.V.'s total assets?
Immatics N.V. (IMTX) had $660.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Immatics N.V.'s capital expenditures?
Immatics N.V. (IMTX) invested $7.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Immatics N.V. spend on research and development?
Immatics N.V. (IMTX) invested $215.7M in research and development during fiscal year 2025.
What is Immatics N.V.'s current ratio?
Immatics N.V. (IMTX) had a current ratio of 11.72 as of fiscal year 2025, which is generally considered healthy.
What is Immatics N.V.'s liabilities-to-equity ratio?
Immatics N.V. (IMTX) had a liabilities-to-equity ratio of 0.16 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is Immatics N.V.'s return on assets (ROA)?
Immatics N.V. (IMTX) had a return on assets of -34.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Immatics N.V.'s P/E ratio?
Immatics N.V. (IMTX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $1.1B as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Immatics N.V.'s price-to-sales ratio?
Immatics N.V. (IMTX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $1.1B as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Immatics N.V.'s Piotroski F-Score?
Immatics N.V. (IMTX) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Immatics N.V.'s earnings high quality?
Immatics N.V. (IMTX) reported a net loss of $230.6M while operations used $207.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Immatics N.V. cover its interest payments?
Immatics N.V. (IMTX) reported an operating loss of $213.6M against $1.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.